S
CRVS icon

SignatureFD’s Corvus Pharmaceuticals CRVS Stock Holding History

SignatureFD’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14K Sell
76
-60
-44% -$833 ﹤0.01% 3240
2026
Q1 		$1.99K Buy
136
+60
+79% +$958 ﹤0.01% 3059
2025
Q4 		$585 Hold
76
– – ﹤0.01% 3211
2025
Q3 		$560 Buy
+76
New +$389 ﹤0.01% 3175
2025
Q1 		– Sell
-224
Closed -$1.2K – 3344
2024
Q4 		$1.2K Buy
+224
New +$1.67K ﹤0.01% 2992

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SignatureFD's CRVS Position: Q2 2026 in Review

SignatureFD reduced its Corvus Pharmaceuticals (CRVS) stake by 44% in Q2 2026, selling an estimated $833 and leaving 76 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #3240.

SignatureFD first reported a position in CRVS in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.99K in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • SignatureFD held 76 shares of Corvus Pharmaceuticals worth $1.14K as of Q2 2026.
  • SignatureFD sold 60 Corvus Pharmaceuticals shares in Q2 2026, an estimated $833.
  • Corvus Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3240 holding.
  • SignatureFD first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • SignatureFD's Corvus Pharmaceuticals position peaked at $1.99K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.